High Response Rate to Pembrolizumab in Unresectable Desmoplastic Melanoma Trial
Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after
High Response Rate to Pembrolizumab in Unresectable Desmoplastic Melanoma Trial
